Catalyst

Slingshot members are tracking this event:

Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AMGN

100%
Euronext Brussels: UCB

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 22, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Frame Study, Postmenopausal Women With Osteoporosis, Romosozumab, Sclerostin, Protein, Bone Resorption, Inhibiting Sclerostin, Monoclonal Antibody, Frame